Helus Pharma Shares Fall 21% Despite Phase 3 HLP003 Trial Meeting Primary Endpoint
Helus Pharma (NASDAQ:HELP) shares dropped 21% despite positive Phase 3 trial results for HLP003 in treating major depressive disorder. The trial met primary and secondary endpoints, showing significant improvement in depression symptoms compared to placebo. The company plans to release further results in late 2027.
How this was made

The 30-second read
Why it matters
The Phase 3 APPROACH trial met its primary efficacy endpoint, yet the stock fell 21% as investors weighed commercial and safety considerations.
Market read
The announcement triggered a sharp intra‑day sell‑off, highlighting the sensitivity of biotech stocks to trial outcomes.
What to watch
Safety profile details and upcoming Phase 3 EMBRACE results could mitigate current concerns.
Background
Helus Pharma (NASDAQ:HELP) is a clinical‑stage biotech focused on novel treatments for major depressive disorder.
Ticker impact
Helus Pharma reported Phase 3 trial results for HLP003, meeting primary endpoint but shares fell 21% on the news.
likely continued pressure as investors reassess commercial potential after the steep sell‑off.
The market already reacted with a 21% decline; further downside is possible if investors view safety signals or market expectations as unmet.
Market effects
The result may influence sentiment toward other biotech firms developing depression therapies.
Limited to US‑listed biotech and pharma stocks.
Modest; primarily affects investors focused on mental‑health drug pipelines.
Counterpoint
The trial met its primary endpoint with strong statistical significance, suggesting upside if the market overreacts to the price drop.
Key entities
- companyHelus Pharma Inc.
US‑listed biotech developing HLP003 for depression.




